Pyoderma gangrenosum with systemic and pulmonary involvement in a toddler
Corresponding Author
Despoina N Maritsi
Second Department of Pediatrics, “P. & A. Kyriakou” Children's Hospital, Medical School, Athens University, Athens, Greece
Correspondence: Despoina N. Maritsi, MD, MSc, PhD, MRCPCH, Second Department of Pediatrics, “P. & A. Kyriakou” Children's Hospital, Medical Faculty, National and Kapodestrian University of Athens, Athens, Greece. Email: [email protected]Search for more papers by this authorKyriaki Tavernaraki
Department of Medical Imaging and Interventional Radiology, ‘Sotiria’ General Hospital, Athens, Greece
Search for more papers by this authorGeorge Vartzelis
Second Department of Pediatrics, “P. & A. Kyriakou” Children's Hospital, Medical School, Athens University, Athens, Greece
Search for more papers by this authorCorresponding Author
Despoina N Maritsi
Second Department of Pediatrics, “P. & A. Kyriakou” Children's Hospital, Medical School, Athens University, Athens, Greece
Correspondence: Despoina N. Maritsi, MD, MSc, PhD, MRCPCH, Second Department of Pediatrics, “P. & A. Kyriakou” Children's Hospital, Medical Faculty, National and Kapodestrian University of Athens, Athens, Greece. Email: [email protected]Search for more papers by this authorKyriaki Tavernaraki
Department of Medical Imaging and Interventional Radiology, ‘Sotiria’ General Hospital, Athens, Greece
Search for more papers by this authorGeorge Vartzelis
Second Department of Pediatrics, “P. & A. Kyriakou” Children's Hospital, Medical School, Athens University, Athens, Greece
Search for more papers by this author
References
- 1 Callen JP. Pyoderma gangrenosum. Lancet 1998; 351: 581–5.
- 2 Binus AM, Qureshi AA, Li VW, Winterfield LS. Pyoderma gangrenosum: A retrospective review of patient characteristics, comorbidities and therapy in 103 patients. Br. J. Dermatol. 2011; 165: 1244–50.
- 3 Ampuero J, Rojas-Feria M, Castro-Fernández M, Cano C, Romero-Gómez M. Predictive factors for erythema nodosum and pyoderma gangrenosum in inflammatory bowel disease. J. Gastroenterol. Hepatol. 2014; 29: 291–5.
- 4 Aloi M, Cucchiara S. Extradigestive manifestations of IBD in pediatrics. Eur. Rev. Med. Pharmacol. Sci. 2009; 13 (Suppl 1): 23–32.
- 5 Almeida de JA, Goldbach-Mansky R. Monogenic autoinflammatory diseases: Concept and clinical manifestations. Clin. Immunol. 2013; 147: 155–74.
- 6 Kurzrock R, Cohen PR. Mucocutaneous paraneoplastic manifestations of hematologic malignancies. Am. J. Med. 1995; 99: 207–16.
- 7 Chahine B, Chenivesse C, Tillie-Leblond I et al. Pulmonary manifestations of pyoderma gangrenosum. Presse Med. 2007; 36: 1395–8.
- 8 Liu ZH, Lu XL, Fu MH, Zhang GY, Liu WD. Pyoderma gangrenosum with pulmonary involvement? Eur. J. Dermatol. 2008; 18: 583–5.
- 9 Wollina U. Pyoderma gangrenosum: A review. Orphanet J. Rare Dis.2007; 2: 19.
- 10 Ahronowitz I, Harp J, Shinkai K. Etiology and management of pyoderma gangrenosum: A comprehensive review. Am. J. Clin. Dermatol. 2012; 13: 191–211.
- 11 Cummins DL, Anhalt GJ, Monahan T, Meyerle JH. Treatment of pyoderma gangrenosum with intravenous immunoglobulin. Br. J. Dermatol. 2007; 157: 1235–9.
- 12 Kreuter A, Reich-Schupke S, Stücker M, Altmeyer P, Gambichler T. Intravenous immunoglobulin for pyoderma gangrenosum. Br. J. Dermatol. 2008; 158: 856–7.
Citing Literature
